On Wednesday, Scotiabank adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE), decreasing the value goal to $17 from the earlier $19 whereas sustaining a Sector Outperform score on the inventory.
The choice follows a latest downturn within the firm’s inventory worth as a result of unsuccessful end result of the KINETIC-2 research, which examined SAGE-324 for the remedy of important tremor.
The analyst from Scotiabank advises buyers to think about growing their holdings in Sage Therapeutics, citing the inventory’s method to what’s termed “deep value territory.”
Regardless of the setback from the KINETIC-2 research, the analyst factors out that the corporate’s shares are at present buying and selling close to their estimated money stability for the second quarter of 2024, which is roughly $10.37 per share.
This valuation doesn’t absolutely account for Sage Therapeutics’ proper to 50% of the income from gross sales of Zurzuvae, an oral medicine not too long ago authorised for the remedy of post-partum melancholy.
Market suggestions suggests a excessive stage of enthusiasm for Zurzuvae, though there are notable challenges with payor acceptance. Even with conservative gross sales projections for Zurzuvae, the analyst believes that the corporate’s shares have the potential to be valued at practically $29 within the occasion of an organization sale. If the gross sales estimates for Zurzuvae are overly optimistic by as a lot as 75%, the shares may nonetheless be value round $13, in response to the analyst’s evaluation.
Sage Therapeutics additionally has different prospects in its pipeline, with ongoing potential for dalzanemdor, a drug being investigated for the remedy of Huntington’s and Alzheimer’s illnesses. Taking into consideration the present scenario and the remaining potential of the corporate’s portfolio, the analyst has set the brand new value goal for Sage Therapeutics at $17.
In different latest information, Sage Therapeutics has seen a number of changes by analysts following varied trial outcomes and gross sales efficiency opinions. Mizuho Securities has lowered its value goal for Sage Therapeutics to $13 from the earlier $16, following disappointing outcomes from the KINETIC-2 Section 2b trial of SAGE-324. The trial didn’t meet its main endpoint, resulting in the halt of SAGE-324’s improvement for Important Tremor.
JPMorgan has additionally downgraded Sage Therapeutics’ inventory from Chubby to Impartial, revising the value goal downward to $12.00. This resolution displays a cautious outlook on the near-term potential for Sage’s product, Zurzuvae, aimed toward treating postpartum melancholy.
In distinction, Scotiabank has reaffirmed its Sector Outperform score with a gentle value goal of $19.00, citing robust recognition and satisfaction with Zurzuvae. In the meantime, H.C. Wainwright maintained its Impartial score with a constant value goal of $25.00, regardless of a latest setback in a Parkinson’s Illness trial.
InvestingPro Insights
As Scotiabank revises its stance on Sage Therapeutics following the KINETIC-2 research outcomes, InvestingPro information and suggestions supply extra views on the corporate’s monetary well being and inventory efficiency. With a market capitalization of $624.69 million and a latest value shut of $10.38, Sage Therapeutics is buying and selling close to its 52-week low, which aligns with the analyst’s view of the inventory getting into “deep value territory”. The numerous income progress during the last twelve months, at an astonishing 868.96%, means that regardless of latest challenges, the corporate has seen appreciable enlargement in gross sales, which might be a optimistic sign for buyers contemplating the potential of Zurzuvae.
An InvestingPro Tip highlights that Sage holds more money than debt on its stability sheet, which supplies a cushion in opposition to the corporate’s speedy money burn and aligns with the Scotiabank analyst’s reference to the corporate’s money stability. Moreover, with the inventory having taken a substantial hit over the previous six months, down by 60.49%, buyers would possibly discover the present valuation an opportune entry level. Sage’s liquid property additionally exceed short-term obligations, which is a reassuring signal of near-term monetary stability.
For buyers looking for a deeper dive into Sage Therapeutics’ financials and inventory efficiency, InvestingPro provides a wealth of extra suggestions. There are at present 11 extra suggestions accessible, which will be accessed by way of the platform. readers can use the coupon code PRONEWS24 to stand up to 10% off a yearly Professional and a yearly or biyearly Professional+ subscription, offering a complete toolkit for knowledgeable funding selections.
This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.
